Hyperplasia is an increase in the number of cells in a tissue or organ, causing it to enlarge. Unlike cancer, hyperplasia is typically a controlled response to a specific stimulus, and it usually reverses once that stimulus is removed. It can be a completely normal part of how your body adapts to changing demands, or it can signal a hormonal imbalance or chronic irritation that needs attention.
How Hyperplasia Works
Your body’s tissues grow in two basic ways. Cells can get bigger (hypertrophy), or cells can multiply to create more of themselves (hyperplasia). Both result in a larger tissue, but through different mechanisms. In many situations, both processes happen together. Fat tissue is a good example: fat cells first grow larger to store more energy, and only later does the body produce additional fat cells. Research in adipose tissue has shown that hypertrophy tends to be driven by diet, while hyperplasia is more influenced by genetics.
The key feature of hyperplasia is that the new cells look and behave normally. They’re arranged in normal patterns within the tissue, and they continue performing their usual functions. This is what separates hyperplasia from cancer. Hyperplastic growth is reversible because it depends on an outside signal. Neoplasia, or cancer, is autonomous, meaning the cells keep dividing on their own regardless of whether the original trigger is still present.
Normal Hyperplasia in the Body
Not all hyperplasia is a problem. Your body uses it routinely to meet increased demands or recover from injury.
Hormonal hyperplasia happens during normal life stages. Breast tissue proliferates during puberty and pregnancy in response to hormonal signals. The uterine lining thickens each menstrual cycle as cells multiply under the influence of estrogen. These are tightly regulated processes that reverse when hormone levels shift.
Compensatory hyperplasia is your body’s way of rebuilding after damage. The classic example is the liver. After a major injury or surgical removal of up to 70% of liver tissue, the remaining liver cells begin dividing while still performing all their normal jobs: regulating blood sugar, producing blood proteins, secreting bile, and metabolizing drugs. Within roughly 72 hours in animal models, a significant wave of cell division is underway, and the liver can restore its original mass. Pancreatic insulin-producing cells and the cells lining blood vessels also regenerate through this mechanism.
Pathological Hyperplasia
When hyperplasia is driven by abnormal signals, particularly excessive hormone levels or chronic irritation, it becomes pathological. The cells themselves are still normal, but they’re multiplying more than they should.
Excessive hormonal stimulation is the most common cause. When a hormone acts on its target tissue for too long or at too high a level, the tissue keeps growing beyond what’s needed. Thyroid glands can develop a goiter when stimulated by excess thyroid-stimulating hormone or by stimulating antibodies. Adrenal glands and parathyroid glands can undergo primary hyperplasia, where the gland overproduces its hormone while simultaneously growing in size. In these cases, the hyperplasia and the hormone excess feed into each other.
Chronic irritation or inflammation can also trigger pathological hyperplasia. When tissue is repeatedly damaged, the body’s repair signals stay turned on, leading to excess cell production. Over long periods, this type of hyperplasia can sometimes develop into dysplasia, where the cells start to look abnormal under a microscope.
Benign Prostatic Hyperplasia
One of the most common forms of hyperplasia affects the prostate gland. Benign prostatic hyperplasia (BPH) becomes increasingly prevalent as men age. Autopsy studies have found it in about 8% of men in their 30s, 50% by their 50s, and 80% by their 80s. The enlarged prostate presses on the urethra, making urination slow, frequent, or difficult.
The exact cause involves a combination of hormonal changes, inflammation, oxidative stress, and growth factor signaling. BPH is not cancer and doesn’t directly become cancer, though both conditions become more common with age. Treatment ranges from monitoring and lifestyle changes for mild symptoms to medications that shrink the prostate or relax the surrounding muscles, and in some cases procedures to remove excess tissue.
Endometrial Hyperplasia
The uterine lining is particularly sensitive to prolonged estrogen exposure without enough progesterone to balance it. This imbalance can cause the endometrium to thicken excessively, a condition called endometrial hyperplasia. It commonly causes irregular or heavy menstrual bleeding.
The World Health Organization now classifies endometrial hyperplasia into two categories. Hyperplasia without atypia is a benign overgrowth that typically regresses once hormone levels normalize. Fewer than 1 to 3% of these cases progress to cancer, and only when estrogen dominance persists over a long period. Atypical hyperplasia is a different situation entirely. The cells show genetic mutations commonly found in endometrial cancer, and 25 to 33% of women diagnosed with atypical hyperplasia already have coexisting invasive cancer at the time of diagnosis. Up to 60% will develop invasive cancer if untreated.
Diagnosis requires a biopsy, where a pathologist examines the tissue under a microscope. They look at how densely packed the glands are relative to the surrounding tissue, whether the cells have lost their normal uniform appearance, and whether the nuclei show irregular shapes or prominent features. This distinction between typical and atypical hyperplasia is one of the most important calls a pathologist makes, because it determines whether treatment is conservative hormonal management or surgery.
Atypical Hyperplasia and Cancer Risk
The word “hyperplasia” on a biopsy report doesn’t mean cancer. But the word “atypical” in front of it changes the picture significantly.
In breast tissue, atypical ductal hyperplasia (ADH) is not cancer itself but acts as a marker for future breast cancer risk. Women diagnosed with ADH carry roughly a 30% lifetime risk of developing breast cancer. That risk accumulates gradually: about 7% of women with ADH develop breast cancer within five years, and 13% within ten years, according to data from Johns Hopkins Medicine. This elevated risk applies to both breasts, not just the side where the atypical cells were found, which is why it’s considered a risk marker rather than a direct precursor.
In the endometrium, as noted above, the jump in risk from typical to atypical hyperplasia is dramatic. Atypical hyperplasia carries a relative risk 14 to 45 times higher than normal for developing invasive endometrial cancer. The biology reflects this: atypical cells already carry many of the same genetic mutations found in established cancers, including mutations in tumor suppressor genes and growth signaling pathways.
How Hyperplasia Is Diagnosed
Hyperplasia is a tissue-level diagnosis, meaning it’s identified by looking at cells under a microscope rather than through blood tests or imaging alone. Imaging like ultrasound or MRI may suggest that a tissue is thicker or larger than expected, but confirming hyperplasia and determining whether it’s typical or atypical requires a biopsy.
For endometrial hyperplasia, this usually means an office-based procedure where a thin instrument collects a sample of the uterine lining. For prostate concerns, biopsies are taken with needle cores guided by ultrasound. Breast atypical hyperplasia is often discovered incidentally during a biopsy prompted by a mammogram finding.
Pathologists evaluate the ratio of glands to surrounding tissue, the architecture of those glands (whether they’re branching, dilated, or crowded), and the appearance of individual cell nuclei. The presence of nuclear irregularities, loss of normal cell orientation, and differences between the abnormal area and the surrounding normal tissue are what distinguish atypical hyperplasia from the benign form. This assessment remains somewhat subjective, and difficult cases may be sent for a second opinion or evaluated with molecular markers to improve accuracy.